### Highlights of This Issue 5809

#### SPECIAL FEATURES

**CCR Translations**
- **5811** It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma  
  Arman Jahangiri and William A. Weiss  
  See related article, p. 5940

**CCR New Strategies**
- **5814** New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK  
  Giuseppe Barone, John Anderson, Andrew D.J. Pearson, Kevin Petrie, and Louis Chesler

**CCR Perspectives in Drug Approval**
- **5822** Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases  
  Michel D. Wissing, Fijs W.B. van Leeuwen, Gabri van der Pluijm, and Hans Gelderblom

**CCR Drug Updates**
- **5828** Ponatinib—A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia  
  Olga Frankfurt and Jonathan D. Licht

**Molecular Pathways**
- **5835** Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer  
  Bo Li and M. Celeste Simon
- **5842** Molecular Pathways: Estrogen Pathway in Colorectal Cancer  
  Afsaneh Barzi, Annika Medea Lenz, Melissa J. Labonte, and Heinz-Josef Lenz

**Perspectives**
- **5849** The Cancer Diaspora: Metastasis beyond the Seed and Soil Hypothesis  
  Kenneth J. Pienta, Bruce A. Robertson, Donald S. Coffey, and Russell S. Taichman

### Review
- **5856** Targeting Fibroblast Growth Factor Pathways in Prostate Cancer  
  Paul G. Corn, Fen Wang, Wallace L. McKeegan, and Nora Navone

### HUMAN CANCER BIOLOGY
- **5867** Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization  
  Zhi-Zhou Shi, Li Zhang, Yan-Yi Jiang, Jia-Jie Hao, Yu Zhang, Tong-Tong Zhang, De-Chen Lin, Shu-Guang Liu, Bo-Shi Wang, Ting Gong, Qi-Min Zhan, and Ming-Rong Wang

- **5879** Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma  

- **5890** Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features  
  Fortunato Morabito, Laura Mosca, Giovanna Cutrona, Luca Agnelli, Giacomo Tuana, Manuela Ferracin, Barbara Zagatti, Marta Lionetti, Sonia Fabris, Francesco Maura, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Carlotta Massucco, Anna Grazia Becchia, Sabrina Bossio, Laura De Stefano, Fiorella Ibarzicu, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzis, Pierfrancesco Tassone, Massimo Negrini, Sara Monti, Davide Rossi, Gianluca Gaidano, Manlio Ferrarini, and Antonino Neri

- **5901** A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer  
  Christian Marin-Muller, Dali Li, Uddalak Bharadwaj, Min Li, Changyi Chen, Sally E. Hodges, William E. Fisher, Qianxing Mo, Mien-Chie Hung, and Qizhi Yao
Clinical Cancer Research

IMAGING, DIAGNOSIS, PROGNOSIS

5984
Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008

Ingrid J.G. Burvenich, Fook T. Lee, Glenn A. Cartwright, Graeme J. O’Keeffe, Dahna Makris, Diana Cao, Sylvia Gong, Anderly C. Chueh, John M. Mariadason, Martin W. Brenchley, Robert A. Beckman, Kosaku Fujiiwara, Reinhardt von Roemeling, and Andrew M. Scott

CANCER THERAPY: PRECLINICAL

5940
Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo


See related article, p. 5811

5994
Proteome Profiling of Cancer-Associated Fibroblasts Identifies Novel Proinflammatory Signatures and Prognostic Markers for Colorectal Cancer

Sofía Torres, Rubén A. Bartolomé, Marta Mendes, Rodrigo Barderas, M. Jesús Fernández-Aceñero, Alberto Peláez-García, Cristina Peña, María López-Lucendo, Roi Villar-Vázquez, Antonio García de Herreros, Félix Bonilla, and J. Ignacio Casal

CANCER THERAPY: CLINICAL

6020
A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, and George D. Demetri

6030
Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment


Clinical Cancer Research
Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs
Kehua Wu, Larry House, Jacqueline Ramirez, Michael J. Seminerio, and Mark J. Ratain

LETTER TO THE EDITOR
Aflibercept and Its Role in the Treatment of Colorectal Cancer—Letter
Frank A. Sinicrope, Eric E. Williamson, and Daniel D. Borgeson

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
Barbara Pardini, Fabio Rosa, Elisa Barone, Cornelia Di Gaetano, Jana Slysikov, Jan Novotny, Miroslav Levy, Sonia Garritano, Ludmila Vodickova, Tomas Buchler, Federica Gemignani, Stefano Landi, Pavel Vodicka, and Alessio Naccarati

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER
The cover shows primary cultures of CAFs from colorectal cancer patients: immunofluorescence analyses for α-SMA expression in human primary colon CAFs from two different patients with low and high α-SMA level. For details, see the article by Herrera and colleagues on page 5914 of this issue.